Introduction
The Neu (ErbB-2, HER2) proto-oncogene, a member of the epidermal growth factor receptor (EGFR) gene family, is strongly implicated in mouse mammary tumorigenesis and human breast cancer (Olayioye et al., 2000) . In transgenic animal models, mouse mammary tumor virus (MMTV)-driven expression of an activated form of the Neu transgene in mammary epithelia induced metastatic mammary tumors (Muller et al., 1988) . Importantly, promising results have been obtained in clinical treatment of patients suffering from ErbB-2-overexpressing metastatic cancer using antiErbB-2 antibody trastuzumab (Herceptin) (Slamon and Pegram, 2001) . Therefore, abnormal activation or overexpression of the Neu protein tyrosine kinase evidently has a causal role in mammary tumorigenesis. However, the molecular mechanism underlying cell transformation by Neu/ErbB-2 is not fully understood, nor is it clear what pathways downstream of oncogenic Neu/ErbB-2 confer metastatic potential.
Identification of cytoplasmic proteins involved in downstream signaling events is crucial for understanding the physiological/pathological functions of Neu. It was recently recognized that scaffolding adapter proteins might play critical roles in coupling/amplifying signals emanating from growth factor receptors and, in particular, accumulating experimental data suggest a putative role of Gab2 in Neu-induced breast cancer. Like other Gab family members, Gab2 possesses a pleckstrin homology PH domain at the N-terminus, proline-rich motifs, and multiple tyrosine residues that couple with SH2-containing molecules, in a phosphorylation-dependent manner (Liu and Rohrschneider, 2002; Gu and Neel, 2003) . Elevated expression of Gab2 has been found in human primary breast cancer specimens and cell lines (Daly et al., 2002) . Gab2 is tyrosine-phosphorylated following stimulation with heregulin or EGF in MCF-7 human breast cancer cells (Daly et al., 2002) , and overexpression of Gab2 in MCF-10A cells increased cell proliferation and altered growth factor dependency (Brummer et al., 2005) . In transgenic mice, overexpression of Gab2 accelerated NeuNT-induced mammary tumorigenesis (Bentires-Alj et al., 2006) . Notably, human Gab2 maps to a region (11q13-14) that is frequently amplified in breast cancer cells (Yamada et al., 2001) , and Gab2 is on a list of genes for prediction of lymphoid metastasis in breast cancer (Huang et al., 2003) . Together, these results point to a potential role of Gab2 in breast cancer development, although a direct physiological evidence for such a role has not been obtained.
In this study, we generated a Gab2 knockout mouse line and examined the impact of Gab2 deficiency on Neu-induced mammary tumorigenesis. Using two different transgenic mouse tumor models (MMTV-NeuYD and MMTV-Neu2-5), we found that deletion of Gab2 had a modest impact on initiation/progression of mammary tumors but severely suppressed lung metastasis, indicating a novel Gab2 activity in breast cancer.
Results

Generation of compound mutant mice
We generated a Gab2 knockout mouse strain by deleting exon 4, encoding amino acids 208-400, and also introducing a frameshift mutation thereafter (Figure 1a) . Homozygous mutant mice were born with the expected Mendelian frequency with no obvious abnormal phenotype.
To determine the requirement for Gab2 in mammary tumorigenesis, we crossed Gab2 mutant mice with two different Neu transgenic mouse strains, MMTV-NeuYD and MMTV-Neu2-5 (Siegel et al., 1999; Dankort et al., 2001) . The Neu2-5 transgene, possessing an in-frame deletion of five amino acid residues in the extracellular domain, encodes a constitutively active form of the tyrosine kinase and induces metastatic mammary tumors within an average of 161 days (Siegel et al., 1999) . The NeuYD mutant (MMTV-Neu ndl -YD5), containing the same extracellular domain deletion as Neu2-5 and retaining only one of the four cytoplasmic tyrosine residues (Y1227) for recruitment of Shc, potently induces mammary tumorigenesis with low metastatic potential (Dankort et al., 2001) . Gab2 À/À mice were crossed with MMTV-NeuYD or MMTV-Neu2-5 mice, and mammary tumor development was compared between NeuYD/Gab2
þ /À and Neu2-5/Gab2 À/À mice. Genotyping of the Neu transgenes and the Gab2 mutant allele was performed by polymerase chain reaction (PCR) analysis of tail genomic DNA (Figure 1b) , and deletion of Gab2 was confirmed by immunoblot analysis using an antiGab2 antibody (Figure 1c) .
Gab2 deletion had a modest impact on mammary tumor initiation/growth The effect of Gab2 ablation on mammary tumor development was first evaluated in MMTV-NeuYD transgenic mice. To do so, cohorts of virgin females were monitored for tumor appearance by physical palpation. Both of NeuYD/Gab2
and NeuYD/ Gab2 À/À animals developed mammary tumors between 4 and 8 months (Figure 2a) . Although there was a slight delay in tumor initiation in Gab2 À/À mice as compared with Gab2 þ /À mice, the difference between the two groups was not statistically significant ( Figure 2b ). As revealed by haematoxylin and eosin (H&E) staining, there was also no difference in tumor morphogenesis and patterns between Gab2 þ /À and Gab2 À/À animals ( Figure 2c ). After detection of tumors, tumor volumes were measured to evaluate tumor growth (Figure 2d ). Liner regression analysis indicated no significant difference between NeuYD/Gab2 þ /À and NeuYD/Gab2
À/À animals (P>0.05, n ¼ 7-10). Therefore, Gab2 deficiency did not have a dramatic impact on initiation or growth of mammary tumors induced by MMTV-NeuYD, a potent oncogene in mice. As Gab2 may be involved in signaling pathways other than that mediated by Shc, which is preserved in the NeuYD mice, we also crossed Gab2 mutant mice with another transgenic line MMTV-Neu2-5. Similar to previous observations (Siegel et al., 1999) , mammary tumors were detected in this transgenic line after a longer latent period compared to the MMTV-NeuYD mice ( Figure 2b ). In double mutants, Gab2 deficiency also slightly delayed tumor onset, but the difference was insignificant between Neu2-5/Gab2 þ /À and Neu2-5/ Gab2 À/À mice ( Figure 2b ). As Gab2 is frequently overexpressed in human breast cancer cells, we assessed Gab2 protein levels in mammary tumor tissue, tissue adjacent to tumors and normal ductal epithelium in both NeuYD/Gab2 þ /À and Neu2-5/Gab2 þ /À mice. As depicted in Figure 3a and b, Gab2 protein contents were significantly increased in tumor and tumor-adjacent tissues compared with normal ductal epithelium in these Gab2-positive tumorbearing mice. Therefore, our experiments with two different transgenic mouse tumor models argue that although it is overexpressed in developed mammary tumors and possibly involved in Neu-induced tumorigenesis, Gab2 may be dispensable for tumor initiation and growth.
Decreased lung metastasis of Gab2-deficient mammary tumors
We then asked whether ablation of Gab2 affected tumor-distant metastasis in MMTV-Neu2-5 mice, which have been shown to develop highly metastatic tumors (Siegel et al., 1999) . Lung tissues of tumor-bearing mice were excised and examined by H&E staining for evidence of tumor metastasis approximately 20 days after tumor appearance. As shown in Figure 4a , metastatic lesions were detected in 75% (6/8) of Neu2-5/Gab2 þ /À animals examined, but the incidence of lung metastasis was declined to 25% (2/8) in Neu2-5/Gab2 À/À animals. Furthermore, histological analysis indicated that even in Neu2-5/Gab2
À/À mice with tumor cell colonization, there was a significant decrease in the number and size of tumor colonies in lung tissues (Figure 4a and b). Thus, Gab2 deficiency leads to a significant alleviation of mammary tumor metastasis.
Normal proliferation but attenuated migration of Gab2
À/À cancer cells To determine Gab2 function in Neu-induced malignant cell growth, we isolated explants from mammary tumors Role of Gab2 in mammary tumorigenesis and metastasis Y Ke et al and established primary cell cultures in vitro. Cell proliferation assay was performed by using RT-CES system. Gab2 À/À cells displayed a similar proliferation rate as Gab2 þ /À cells, as represented by normalized cell doubling time (Figure 5a ). This observation is consistent with the normal tumor initiation/growth seen in Gab2 À/À animals. We then assessed cell migration and found that Gab2 À/À cancer cells displayed a marked reduction in cell motility compared with Gab2 þ /À cells in vitro (Figure 5b) , supporting a role of Gab2 in promoting tumor cell invasion/metastasis in vivo.
Gab2 deficiency leads to impaired Erk activity
To identify signaling pathways associated with impaired motility of Gab2-deficient primary tumor cells, we examined the activation status of Erk and Akt, two effectors functioning in different pathways known to be upregulated in mammary carcinogenesis induced by Neu (Amundadottir and Leder, 1998; Dankort et al., 2001) . In response to EGF stimulation in vitro, Gab2-deficient tumor cells displayed decreased phospho-Erk (p-Erk) signals, while maintaining a normal level of p-Akt (Figure 6a ). We further measured p-Erk and p-Akt levels directly in lysates of tumors excised from Neu2-5/Gab2 þ /À and Neu2-5/Gab2 À/À animals. As shown in Figure 6b and c, whereas tumor lysates derived from Neu2-5/Gab2 þ /À mice displayed p-Erk levels elevated to variable extents, p-Erk was almost undetectable or detected at very low levels in non-invasive Neu2-5/ Gab2 À/À tumors. p-Akt levels were similar between Neu2-5/Gab2 þ /À and Neu2-5/Gab2 À/À tumors in general. We further assessed the distinct roles of Erk and Akt in mammary tumors, by examining cell responses to Mek and phosphatidylinositol 3-kinase (PI3K) inhibitors, PD98059 and LY294002, respectively. As shown in Figure 7a , Gab2 þ /À and Gab2 À/À tumor cells exhibited similar proliferation and survival patterns following treatment with either of the two inhibitors. Inhibition of PI3K activity severely suppressed tumor cell viability, whereas the Mek inhibitor exerted only a modest effect on tumor cell growth/survival. Determination of the IC 50 further indicated that inhibition of PI3K had a more profound impact on MMTV-Neu-induced tumor cell viability and proliferation than did inhibition of Mek (Figure 7b ). However, cell migration was . Right panel is the densitometric analysis of Gab2 expression levels in tumor and normal tissues. Gab2 levels were quantified and normalized against actin expression using NIH ImageJ software. The data for tumor were averaged from #1-4 and #9-11 samples, and data for normal tissue were calculated from #12-14 samples (Po0.05, n ¼ 3-7). (b) Immunohistochemical analysis of Gab2 expression in normal mammary, Gab2 þ /À and Gab2 À/À tumor tissue. Mammary tissue and tumors were immunostained with antibodies against mouse Gab2 (red), cytokeratin 18 (K18) (green) and DAPI (blue). Scale bars, 100 mm.
Role of
profoundly affected by inhibition of Erk activation with the Mek inhibitor (Figure 7c ). To establish a role for Gab2 in tumor cell migration, we transfected Gab2
tumor cells with a construct expressing a wild-type Gab2, and evaluated cell migration and Erk activity again. As depicted in Figure 7d and e, reintroduction of Gab2 resulted in enhanced migration in vitro and also elevated EGF-induced p-Erk signals in Gab2 À/À tumor Role of Gab2 in mammary tumorigenesis and metastasis Y Ke et al cells. Collectively, these results indicate that Gab2 deficiency is insufficient to suppress mammary tumor initiation/growth possibly due to normal activation of the PI3K/Akt pathway, and that Gab2 may act to promote tumor cell metastasis by mediating Erk activation by Neu.
Gab2 expression correlates with an invasive phenotype in breast cancer cells
We also compared Gab2 expression levels in several mouse and human breast cancer cell lines. In contrast to lower levels of Gab2 expression in low or non-invasive cell lines MCF7, ZR-75-1, T47D, markedly increased Gab2 contents were detected in highly invasive tumor cell lines such as MDA-MB231, MDA-MB435S and 4T1 (Figure 8a and b) . To establish directly the correlation of Gab2 expression with cell migration, we also transfected MCF7 cells with a Gab2 expression construct (Figure 8c) . The results depicted in Figure 8d show that overexpression of Gab2 significantly enhanced MCF7 cell migration. Consistently, a previous report indicated that knockdown of Gab2 in MCF7 cells suppressed EGF-stimulated cell migration (Meng et al., 2005) . Taken together, these in vitro cell culture results support our observation made in the Neu/Gab2-deficient tumor model that suggests a novel function of Gab2 in mammary tumor metastasis.
Discussion
The current study distinguishes a functional requirement for Gab2 in mammary tumorigenesis and metastasis using a combination of gene knockout and transgenic mouse models. Surprisingly, we found that deletion of Gab2 in mice had a minor effect on initiation or growth of mammary tumors examined in two independent MMTV-Neu transgenic mouse lines, but severely suppressed tumor metastasis to the lung. Consistent with the literature (Daly et al., 2002; Bentires-Alj et al., 2006) , Gab2 expression was elevated in tumor tissues that in normal mammary epithelial tissue in both NeuYD/Gab2 þ /À and Neu2-5/Gab2 þ /À mice. These results suggest that overexpression of Gab2 may promote or at least confer a growth advantage to Neu-induced mammary tumor cells. However, the Gab2 Role of Gab2 in mammary tumorigenesis and metastasis Y Ke et al function may be compensated when Gab2 is homozygously deleted, resulting in normal tumor initiation/ progression in Gab2 À/À animals. Consistent with previous results (Siegel et al., 1999) , we detected lung metastasis in Neu2-5/Gab2 þ /À mice. Importantly, the metastasis rate was potently suppressed in Neu2-5/Gab2
À/À mice, as reflected by decreased number of tumor lesions as well as reduced size of metastasized tumors in the lung. In support of the lung metastasis data in vivo, we found that Gab2-deficient mammary tumor cells displayed impaired motility in vitro, which can be rescued by reintroduction of wild-type Gab2 into Gab2 À/À cells. Consistent to the phenotypes of Gab2 knockout mice and cells, overexpression of Gab2 in MCF7 cells also enhanced cell migration, and there was a good correlation between Gab2 expression levels and cell invasion/metastasis properties among the isolated mouse and human breast cancer cell lines. Furthermore, a recent microarray analysis has included Gab2 into a list of 'metagene', whose expression may be predicative of breast cancer metastasis to lymph nodes (Huang et al., 2003) . Based on these results, we propose that Gab2 may play a more significant role in promoting mouse mammary tumor (hence likely human breast cancer) metastasis rather than in stimulating tumor initiation/growth. This is highly significant, since metastasis is the most important factor in determining the morbidity/mortality of breast cancer patients.
Previous studies have shown that in mammary tumor cells transformed by expression of the MMTV-Neu transgene, the PI3K-Akt and the Ras-Erk pathways are profoundly activated (Amundadottir and Leder, 1998; Dankort et al., 2001) . We detected very low p-Erk tumor cells were transfected with pcDNA3-HA-Gab2 or pcDNA3 empty vector. A total of 10 5 cells per well were assessed for migration in a period of 12 h (*Po0.05, n ¼ 6). (e) Gab2 rescue restored EGF-induced Erk activity. Cells were starved and treated with EGF (20 ng/ml), immunoblotted with antibodies against p-Erk1/2, Erk1/2 and HA-tag (Gab2: pCDNA3-HA-Gab2; Control: pcDNA3 empty vector).
Role of Gab2 in mammary tumorigenesis and metastasis Y Ke et al signals in non-metastatic Gab2 À/À tumor cells with the levels of p-Akt unchanged. We also found that inhibition of PI3K-Akt activity impaired tumor cell growth, while blocking the Erk signal by a Mek inhibitor suppressed cell mobility in vitro. Thus, it appears that the PI3K-Akt and Erk pathways have distinctive roles in Neu-induced mammary tumor initiation/growth and invasion/metastasis, respectively. The PI3K-Akt pathway has been implicated in Neu-overexpressing mammary tumor cell survival and proliferation (Webster et al., 1998) . Notably, similar levels of p-Akt were detected in tumors derived from control (Gab2
) and Gab2 À/À animals, which may account for insufficient suppression of tumorigenesis by homozygous deletion of Gab2. On the other hand, inhibition of Erk activity had no significant effect on tumor cell viability, but impaired cell mobility. This observation is consistent with recent reports suggesting an important role of the Ras-Erk pathway in cell migration and tumor invasion (Sivaraman et al., 1997; Reddy et al., 2003) . Gab2 may act to promote mammary tumor metastasis by mediating Erk activation through the Gab2-Shp2 interaction (BentiresAlj et al., 2006) . A previous report also suggested a positive role of Gab2 in promoting hematopoietic cell migration (Yu et al., 2002) .
In summary, this study suggests a novel mechanism for breast cancer metastasis involving a signaling pathway mediated by Gab2, which could represent a new target in the design of diagnostic and therapeutic strategies for metastatic breast cancer.
Materials and methods
Mice
A targeting construct was engineered to delete exon 4 of Gab2, following a previous procedure (Zhang et al., 2004) . Compound mutant mice were generated by breeding Gab2 À/À mice (129Sv Â C57B6/J) with MMTV-NeuYD or MMTV-Neu2-5 transgenic animals (both FVB) (Siegel et al., 1999; Dankort et al., 2001) .
Cell culture and transfection
Human breast cancer lines MDA-MB-231, MDA-MB-453S, MCF7, ZR-75-1, T-47D and mouse mammary cancer cells 4T1 were obtained originally from ATCC. The plasmid pcDNA3-HA-Gab2 was reported previously (Zhao et al., 1999) . Cell transfection was performed by using GenePorter 2 (Genlantis, San Diego, CA, USA) in accordance with manufacturing specifications.
Mammary tumor analysis
Female animals were monitored and examined for tumor by palpation. Tumor volume was measured by calipers three times weekly after tumor initiation until tumors approached Role of Gab2 in mammary tumorigenesis and metastasis Y Ke et al 2 cm in diameter. For metastasis analysis, the number of tumor cell emboli per section and volumes of metastatic foci observed were recorded. For histological analysis, the inguinal mammary gland was excised. Fixed and stained in carmine alum. Immunoblot analysis was performed using anti-Shp2 (C-18, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-p-Erk and anti-p-Akt (Cell Signaling, Danvers, MA, USA), anti-HA (Sigma-Aldrich, St Louis, MO, USA) and anti-Gab2 (Zhao et al., 1999) .
Primary tumor cell culture and analysis
In vitro culture of mouse mammary tumor cells was described previously (White et al., 2004) . Briefly, tumors were chopped into small pieces and incubated in 2 mg/ml collagenase for 4B6 h at 371C with agitation. Tumor cell aggregates were finely triturated and cultured in F12 Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. Primary cell outgrowth and morphology were examined frequently under a microscope. The explants with fibroblast cells were discarded, and only those tumors cells retained in long-period culture (over 2 months) were used for in vitro assay.
In vitro cell proliferation and viability were assessed in realtime using RT-CES (Real Time Cell Electronic Sensing, ACEABIO, San Diego, CA, USA) (Abassi et al., 2004) . Cells were diluted and seeded at 10 4 /ml in ACEA's Â 96 microtiter plates in 100 ml of culture medium. Cell proliferation was continuously monitored every 30 min using the RT-CES for a period of 24-72 h. For tests with inhibitors, cells were first incubated for 6-8 h and then treated with the indicated concentrations of LY294002 and PD98059 (Cell Signal) or DMSO as control. Cell viability was evaluated based on the measured cell-electrode impedance, as described previously (Xing et al., 2005) .
Tumor cell migration was assessed using a transwell assay (Corning, NY, USA) as described previously with minor modification (Bourguignon et al., 1998) . Human breast cancer cell migration was measured using an RT-CES apparatus, cells were starved 6 h in serum-free medium, and then were seeded at 5 Â 10 4 /ml in 100 ml of serum-free medium in the upper chamber with 8 mM pore size, and the lower chamber contained 10% serum. Cell migration was continuously monitored every 30 min by ACEA's Â 16 microtiter plates for a period of 0-48 h.
